Abstract 2080P
Background
ICIN is a major cause of death in cancer patients (pts). We aimed at identifying incidence of ICIN and predictors of poor prognosis in oncology.
Methods
We designed a multicenter retrospective cohort study on the Greater Paris University Hospitals' (APHP) clinical data warehouse. We included all adult pts with solid cancer hospitalized between January 2016 and December 2021 at APHP with an ICD-10 cancer code, with chemotherapy (chemo) within 30 days prior to the 1st ICIN (defined by the D70 or D611 ICD-10 codes AND a neutrophil count < 500/mm3). The primary outcome was the composite of Intensive Care Unit (ICU) hospitalization or death within 30 days. We collected cancer and chemo characteristics, use of G-CSF, Charlson score items and standard biological values.
Results
Among 141,586 cancer pts, 40,660 received chemo among whom 661 (1.6%) had ICIN. Their median age was 63 years (Interquartile Range (IQR) 54-70) and 330 (50%) were female. The median Charlson score was 10 (IQR 8-11). Documented bacterial or fungal infections were observed in 113 (17%) and 19 (3%) pts, respectively. Main primary cancers were lung (n= 204, 31%) and breast (n=87, 13%). Advanced cancers were present in 551 (83%) pts. The last chemo included platinum in 375 (57%) pts, 331 (50%) were in their 1st line of chemo and 284 (43%) in their 1st cycle of the current line, 149 (23%) had primary prophylactic G-CSF, 27 (4%) had a concomitant SarsCov2 infection. Primary outcome occurred in 120/661 (18%) pts: 57 (9%) were transferred to intensive care and 82 (12%) died within 30 days. After ICIN, 372 (56%) pts received subsequent chemo and 486 (74%) were able to return home. In a multivariate Cox model, higher monocyte count (HR 0.07; 95%CI 0.01-0.44) and albumin nadir (HR 0.93; 95%CI 0.91-0.96) decreased ICU hospitalization risk or death whereas both bacterial (HR 2.12; 95%CI 1.40-3.31) or fungal infection (HR 1.93; 95%CI 1.40-3.31) and concomitant Sars Cov2 infection (HR 2.93; 95%CI 1.41-6.33) increased it. Charlson index (HR: 1.00; 95%CI 0.91-1.10) and primary prophylactic G-CSF (HR 0.83; 95%CI 0.52-1.32) had no prognostic value.
Conclusions
Despite the use of primary prophylactic G-CSF, ICIN is an early event which leads to major complications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Assistance Publique - Hôpitaux de Paris Cancer Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06